ScopeThe purpose of this study was to provide clear evidence that reliably quantifies the association of Asymmetric dimethylarginine (ADMA) levels with the risk of neurovascular diseases.Methods and resultsThe Pubmed, Web of Science, and Embase were systematically searched to identify eligible studies published until August 2024. A total of 31 eligible studies were identified. Pooled results indicated that patients with stroke yielded a higher ADMA level than healthy controls [standardized mean difference (SMD) = 1.02, 95% CI = 0.92–1.12, P = 0.001]. Subgroup analyses showed that geographical location, sample type, number of events and the proportion of male participants were statistically significant sources of heterogeneity. Similarly, a significant association with a pooled risk ratio (RR) of 1.60 (95% CI = 1.60–1.91) was shown between ADMA exposure and the risk of stroke from seven cohort studies. There was a statistically significant difference between ADMA level and small vessel disease (SVD) (SMD = 0.33, 95% CI = 0.07–0.58, p = 0.001). In addition, migraine patients tend to have elevated ADMA levels compared to healthy controls (SMD = 0.39, 95% CI = 0.11–0.67, P = 0.001).ConclusionsOur results indicate that ADMA levels have significant effects in patients with stroke, SVD, and migraine.

中文翻译：

---

不对称二甲基化吉氨酸水平和神经血管疾病风险：系统评价和荟萃分析


范围本研究的目的是提供明确的证据，可靠地量化不对称二甲基精氨酸 （ADMA） 水平与神经血管疾病风险的相关性。方法和结果系统检索了 Pubmed、Web of Science 和 Embase，以确定截至 2024 年 8 月发表的符合条件的研究。共确定了 31 项符合条件的研究。汇总结果表明，卒中患者的 ADMA 水平高于健康对照组 [标准化均数差 （SMD） = 1.02,95% CI = 0.92–1.12，P = 0.001]。亚组分析显示，地理位置、样本类型、事件数量和男性参与者的比例是异质性的统计学显着来源。同样，7 项队列研究显示 ADMA 暴露与中风风险之间存在显著相关性，合并风险比 （RR） 为 1.60 （95% CI = 1.60–1.91）。ADMA 水平与小血管病 （SVD） 之间存在统计学意义差异 （SMD = 0.33,95% CI = 0.07–0.58，p = 0.001）。此外，与健康对照组相比，偏头痛患者的 ADMA 水平往往升高 （SMD = 0.39,95% CI = 0.11–0.67，P = 0.001）。结论我们的结果表明，ADMA 水平对卒中、SVD 和偏头痛患者有显著影响。